Is there a circadian variation in plasma concentrations of etoposide given by prolonged continuous infusion?

被引：3

作者：

Ando, Y

Minami, H

Sakai, S

Shimokata, K

机构：

[1] NAGOYA UNIV,SCH MED,DEPT INTERNAL MED,SHOWA KU,NAGOYA,AICHI 466,JAPAN

[2] JAPANESE RED CROSS,NAGOYA HOSP 1,DEPT INTERNAL MED,NAKAMURA KU,NAGOYA,AICHI 453,JAPAN

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1996年 / 37卷 / 06期

关键词：

etoposide; circadian variation; low-dose infusion; lung cancer;

D O I：

10.1007/s002800050438

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prolonged continuous infusion of low-dose etoposide is a new approach to treating cancer. Whether or not a circadian variation in the plasma levels of etoposide existed was investigated in nine patients with non-small-cell lung cancer. Etoposide was infused for 14 days and blood samples were obtained every 4 h for 1 day. There was no significant circadian variation, and the observed small within-day variations seemed to lack clinical significance.

引用

收藏

页码：616 / 618

页数：3

相关论文

共 13 条

[1]

BJARNASON GA, 1994, P AN M AM SOC CLIN, V13, P233

[2] PHASE-I TRIAL OF 5-DAY CONTINUOUS VENOUS INFUSION OF OXALIPLATIN AT CIRCADIAN RHYTHM-MODULATED RATE COMPARED WITH CONSTANT RATE [J].

CAUSSANEL, JP ;

LEVI, F ;

BRIENZA, S ;

MISSET, JL ;

ITZHAKI, M ;

ADAM, R ;

MILANO, G ;

HECQUET, B ;

MATHE, G .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (12) :1046-1050

[3] A RANDOMIZED TRIAL OF 2 ETOPOSIDE SCHEDULES IN SMALL-CELL LUNG-CANCER - THE INFLUENCE OF PHARMACOKINETICS ON EFFICACY AND TOXICITY [J].

CLARK, PI ;

SLEVIN, ML ;

JOEL, SP ;

OSBORNE, RJ ;

TALBOT, DI ;

JOHNSON, PWM ;

REZNEK, R ;

MASUD, T ;

GREGORY, W ;

WRIGLEY, PFM .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) :1427-1435

[4]

FOCAN C, 1990, Journal of Cancer Research and Clinical Oncology, V116, P1073

[5]

GRECO FA, 1993, CANCER TREAT REV, V19, P35

[6] CIRCADIAN CANCER-THERAPY [J].

HRUSHESKY, WJM ;

BJARNASON, GA .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1403-1417

[7] CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER WITH 4'-0-TETRAHYDROPYRANYL DOXORUBICIN AND CISPLATIN - A RANDOMIZED PHASE-II TRIAL WITH AN EVALUATION OF CIRCADIAN TIMING AND DOSE-INTENSITY [J].

LEVI, F ;

BENAVIDES, M ;

CHEVELLE, C ;

LESAUNIER, F ;

BAILLEUL, F ;

MISSET, JL ;

REGENSBERG, C ;

VANNETZEL, JM ;

REINBERG, A ;

MATHE, G .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) :705-714

[8]

LEVI F, 1994, P AN M AM SOC CLIN, V13, P197

[9] PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF A 14-DAY INFUSION OF ETOPOSIDE IN PATIENTS WITH LUNG-CANCER [J].

MINAMI, H ;

SHIMOKATA, K ;

SAKA, H ;

SAITO, H ;

ANDO, Y ;

SENDA, K ;

NOMURA, F ;

SAKAI, S .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1602-1608

[10] ETOPOSIDE (VP-16-213) - CURRENT STATUS OF AN ACTIVE ANTICANCER DRUG [J].

ODWYER, PJ ;

LEYLANDJONES, B ;

ALONSO, MT ;

MARSONI, S ;

WITTES, RE .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (11) :692-700